Taxation and Regulatory Compliance

Why Are Allergy Drops Not Covered by Insurance?

Unravel the reasons behind health insurance non-coverage for allergy drops. Explore regulatory, scientific, and policy influences on medical treatment decisions.

Allergy drops, also known as sublingual immunotherapy (SLIT), offer an alternative approach to managing allergies without injections. This treatment involves placing small doses of allergens under the tongue, aiming to gradually build the body’s tolerance over time. Despite their use, a common challenge for individuals considering allergy drops is the frequent lack of coverage by health insurance plans.

Regulatory Landscape

The regulatory status of allergy drops in the United States influences insurance coverage. While the allergen extracts used in compounded liquid allergy drops are approved by the U.S. Food and Drug Administration (FDA) for purposes like allergy testing and allergy shots, the compounded liquid formulations themselves are generally not FDA-approved for sublingual immunotherapy. The FDA primarily approves specific products, and compounded allergy drops are customized for individual patients rather than standardized. This distinction means that broad FDA approval for multi-allergen liquid formulations is not typically sought or granted.

In contrast, several specific sublingual immunotherapy tablets, designed to treat single allergens, have received FDA approval. These FDA-approved tablets are more likely to be covered by insurance plans. However, the compounded liquid allergy drops are considered “off-label” use of FDA-approved ingredients, which impacts how insurance companies view them for coverage.

Clinical Evidence and Medical Consensus

Scientific evidence supporting sublingual immunotherapy’s efficacy and safety has grown. Studies indicate SLIT effectively treats allergic rhinitis (hay fever) and allergic asthma. Organizations like the World Allergy Organization (WAO) and the Cochrane Collaboration endorse SLIT for reducing allergy symptoms and medication use.

Medical organizations and clinical guidelines reflect this evidence. Some consensus statements recommend sublingual immunotherapy as a first-line treatment for patients with moderate to severe allergic rhinitis who desire long-term remission. While allergy shots (subcutaneous immunotherapy) are often considered the traditional “gold standard” and may work faster for symptom relief, allergy drops have demonstrated significant effectiveness. Despite the growing clinical support, the heterogeneity in efficacy studies for compounded SLIT drops presents a challenge in establishing a standardized treatment protocol.

Insurance Coverage Determinations

Insurance companies base their coverage decisions on specific criteria, primarily focusing on whether a treatment is deemed “medically necessary.” This determination largely relies on FDA approval and established medical consensus or evidence of effectiveness. For treatments like compounded allergy drops that lack broad FDA approval as standardized products, insurers often classify them as “experimental,” “investigational,” or not medically necessary.

This classification frequently leads to non-coverage, as most health plans have policies excluding treatments considered experimental or investigational. Some private insurance plans may offer partial coverage, but this is not widespread. Individuals can, however, often use funds from Flexible Spending Accounts (FSAs) or Health Savings Accounts (HSAs) to pay for allergy drops, providing a way to cover costs with pre-tax dollars.

Previous

Is Sunscreen an HSA-Eligible Expense?

Back to Taxation and Regulatory Compliance
Next

Does VA Pay for Hospice Room and Board?